LGLucas Wamser Fonseca Gonzaga

Lucas Wamser Fonseca Gonzaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucas Wamser Fonseca Gonzaga has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Physiology-Based Pharmacokinetic Modeling for Prediction of Gentamicin Plasma Profile in Dogs with Renal Dysfunction

    by Kevellyn Silveira Gomes Martins, Lucas Wamser Fonseca Gonzaga, Larissa Alexsandra Felix, Reiner Silveira de Moraes, Priscylla Tatiana Chalfun Guimarães Okamoto, Marcos Ferrante

    Background/Objectives: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model to predict gentamicin therapeutic protocols for dogs with varying degrees of renal function impairment, considering the minimum inhibitory concentrations (MICs) of the infecting bacteria. Methods: The PBPK model was built using PK-Sim® software (OPEN SYSTEMS PHARMACOLOGY), based on pharmacokinetic data available in the literature and information on the physicochemical properties of the drug. Model evaluation included the calculation of the geometric mean fold error (GMFE), weighted and percentage residuals were calculated, as well as the following measures: AFE, AWRi, MWRi, MAWRi, APE%, MPE%, MAPE%, MdPE%, and MdAPE%. Therapeutic efficacy was assessed according to the Probability of Target Attainment (PTA), considering an MIC distribution of 0.25 to 8 μg/mL for different doses (2, 4, 6, 8, and 10 mg/kg) using the PK/PD indices Cmax/MIC ≥ 10, AUC/MIC ≥ 50, and AUC/MIC ≥ 110. To compare the pharmacokinetics of gentamicin between healthy dogs and those with decreased renal function, different GFR values corresponding to stages of renal impairment were used, as determined by clinical biomarkers (microalbuminuria, UPC ≥ 2, sCr ≥ 1.2 mg/dL, sCr ≥ 2.4 mg/dL, and sCr ≥ 5 mg/dL). The risk of toxicity was assessed according to AUC24h ≥ 700 mg·h/L and Cmin ≥ 0.5. Results: The model demonstrated good predictive performance, with a GMFE value of 1.13 meeting the double error criterion, and weighted residuals randomly distributed around 0 (p = 0.3792). Through the calculation of PTA, it was observed that efficacy varied according to the PK/PD index used, but values greater than 90% were obtained for MICs up to 4 μg/mL. The model allowed the estimation of protocols for each stage of renal impairment, considering the GFR of each group and the risk of nephrotoxicity, in association with the optimal dose to ensure therapeutic efficacy. Conclusions: These findings make it possible to propose a dose for the treatment of an infection, considering the MIC and the patient’s GFR stage, thereby reducing the risk of adverse effects without compromising treatment efficacy.

  • Open Access

    Population pharmacokinetic modeling of gentamicin in dogs

    by Kevellyn Silveira Gomes Martins, Larissa Alexandra Félix, Lucas Wamser Fonseca Gonzaga, Karina Krauss Ferraz Vasconcelos, Diego Díaz, João Vitor Fernandes Cotrim de Almeida, Aline Carvalho Pereira, Marcos Ferrante, Nelsa Widerhon

    This study used population pharmacokinetic (popPK) modeling to predict therapeutic efficacy and assess nephrotoxicity risk associated with gentamicin administration in dogs. The model was developed in Monolix 2024 R1 (Lixoft SAS, Simulations Plus Company) using plasma concentrationtime data obtained from the literature. Monte Carlo simulations were subsequently performed in Simulx 2024 (Lixoft SAS, Simulations Plus Company) for gentamicin doses of 2, 4, 6, and 8 mg kg-1 to evaluate therapeutic target attainment and exposure associated with nephrotoxicity risk. The model that best described the observed data was a two-compartment model with linear elimination. Predicted therapeutic efficacy was assessed using the Probability of Target Attainment (PTA) based on the PK/PD target fCmax/MIC ≥ 10 across a range of minimum inhibitory concentrations (MICs). Nephrotoxicity risk was evaluated according to the duration for which plasma gentamicin concentrations remained above the primary nephrotoxicity-risk threshold of 2 μg mL-1. The 8 mg kg-1 regimen achieved PTA values ≥ 90% for pathogens with MIC ≤ 2.0 μg mL-1 and represented the highest-performing simulated regimen among those evaluated. For this regimen, the mean time above the 2 μg mL-1 nephrotoxicity-risk threshold ranged from 4 to 8 hours. These findings support the use of gentamicin against pathogens with MICs ≤ 2 μg mL-1 when administered using extended dosing intervals. However, dose and interval adjustments may be required in critically ill patients. Overall, the popPK approach provides a useful framework for precision dosing, supporting improved predicted efficacy and safety across different dosing regimens.

  • Open Access

    Anesthetic induction with propofol via continuous infusion or bolus in healthy dogs: a randomized clinical trial

    by Gabriela Pereira Souza, Lucas Wamser Fonseca Gonzaga, Pablo Henrique Silva Avelar, Jelieny Aparecida Claudino, Marilda Onghero Taffarel, Marcos Ferrante

    The aim was to compare the administration of propofol via bolus or continuous infusion for anesthetic induction in dogs. Twenty-four healthy adult dogs were randomized into one of two groups: anesthetic induction with intravenous propofol as a 1 mg/kg bolus every 60 seconds (Group B) or continuous infusion at 1 mg/kg/min using a syringe pump (Group CI) following premedication with acepromazine (0.02 mg/kg) and methadone (0.3 mg/kg). The propofol dose, induction time, physiological variables, and the occurrence of myoclonus, hypotension, apnea, desaturation, and hypercapnia after anesthetic induction were evaluated. Independent numerical variables were compared using the Student’s t-test or Mann-Whitney test, while physiological variables were analyzed using repeated measures ANOVA or Friedman test, followed by post hoc comparisons. The significance level was set at P < 0.05. The propofol dose was lower in Group B than in Group CI (3 mg/kg [3 - 3.3] vs. 4.5 mg/kg [3.5 - 5.6], respectively, P = 0.002), and the induction time was shorter in Group B than in Group CI (3 min [3 - 3.25] vs. 4.5 min [3 - 6.25], respectively, P = 0.027) (median and interquartile range). There was no difference in adverse effects between the groups. It is concluded that administering propofol in a 1 mg/kg bolus every 60 seconds allows anesthetic induction with a lower dose and shorter time, with no difference in adverse effects compared to continuous infusion at 1 mg/kg/min.

  • Open Access

    Advances in Canine Anesthesia: Physiologically Based Pharmacokinetic Modeling for Predicting Propofol Plasma Profiles in Canines with Hepatic Impairment

    by Lucas Wamser Fonseca Gonzaga, Beatriz Monte Egito, João Bosco Costa Coelho, Gabriela Pereira Souza, Frederico Severino Martins, Marcos Ferrante

    Background: A PBPK model allows the prediction of the concentration of drug amounts in different tissues and organs over time and can be used to simulate and optimize different therapeutic protocols in healthy and sick individuals. The objective of this work was to create a PBPK model to predict propofol doses for healthy canines and canines with hepatic impairment. Methods: The study methodology was divided into two major phases, in which the first phase consisted of creating the PBPK model for healthy canines, and in the second phase, this model was adjusted for canines with hepatic impairment. The model for healthy canines presented good predictive performance, evidenced by the value of the performance measure of the geometric mean fold error that ranged from 0.8 to 1.25, meeting the double error criterion. The simulated regimen for healthy canines, i.e., of 5 mg/kg (administered as a bolus) followed by a continuous infusion at a rate of 0.13 mg/kg/min, was sufficient and ensured that all simulated subjects achieved the target plasma concentration. Canines with 60% and 40% liver function had infusion rate adjustments to ensure that individuals did not exceed the therapeutic window for maintenance of anesthesia. Results: The results presented in this manuscript are suggestive of the effectiveness and practicality of a PBPK model for propofol in canines, with a particular focus on hepatic impairment.


  • Open Access

    PK/PD integration for intramuscular dose determination of intramuscular sodium cloxacillin for infections caused by Staphylococcus spp in goat

    by L.A. Felix, L.W.F. Gonzaga, B.C.F. Soares, G. Suárez, H.M. Brandão, P.Y. Faccioli-Martins, M. Ferrante

    This study aims to determine therapeutic protocols of intramuscular sodium cloxacillin (IM) in goats with potential antibacterial effects against Staphylococcus spp. We constructed a pharmacokinetic (PK) model of IM, followed by a pharmacokinetic/pharmacodynamic integration (PK/PD). Simulations of different therapeutic protocols were then performed, with the doses ranging from 30 to100 mg/kg every 8, 12, or 24 hours. We calculated the probability to target attainment (PTA) of reach protocol's therapeutic according to the minimum inhibitory concentration (MIC) range of 0.06 to 4 μg/mL. The PK/PD index (PDT) used was "time above the MIC for 40% of the time" (T>MIC ≥40%). Protocols with single administration per day were incapable of achieving PTA ≥ 90% for any of the estimated MICs. However, by decreasing the administration interval, the PTA was increased. Thus, from the dose of 50 mg/kg every 12 hours, a PTA≥ 90% for MICs ≤ 0.5 μg/mL was achieved, while the 30 mg/kg dose every 8 hours was able to achieve a PTA≥ 90% for MICs of 2 μg/mL. The results suggest using 30 mg/kg dose every 8 hours in clinical studies of agents with MICs ≤ 2μg/mL; Nevertheless, the practitioner should adjust the dose in severe patients.


  • Open Access

    Modelo farmacocinético de florfenicol en tilapias (Oreochromis niloticus) sometidas a diferentes temperaturas de crianza

    by Emanuely Ramos Tameirão, Fernando Marcos Rubim, Larissa Alexsandra Felix, Lucas Wamser Fonseca Gonzaga, Humberto De Mello Brandão, Luis David Solis Murgas, Marcos Ferrante

    El objetivo de este trabajo fue desarrollar un modelo farmacocinético de florfenicol en plasma de tilapia (Oreochromis niloticus) sometido a diferentes temperaturas de crianza para estimar la concentración plasmática de los protocolos indicados en los prospectos de productos de florfenicol autorizados en Brasil. Para ello, se creó un modelo farmacocinético a partir de datos previamente publicados sobre la concentración plasmática de florfenicol en tilapia del Nilo sometida a diferentes temperaturas. La construcción del modelo farmacocinético se realizó con el programa Monolix 2020R1 de Lixoft®, partiendo de los datos de farmacocinética plasmática de florfenicol encontrados en la literatura. Las concentraciones plasmáticas de florfenicol se estimaron a partir de tratamientos con dosis de 10, 15 y 20 mg/kg administradas cada 24 horas durante 10 días, a temperaturas de 18, 21, 26 y 30°C, utilizando el programa Simulx 2020 de Lixoft®. Los parámetros de tiempo de latencia de absorción (Tlag) y aclaramiento (Cl) mostraron una correlación positiva con la temperatura, mientras que la constante de absorción (Ka) mostró una correlación negativa. Asimismo, se puede observar que los animales mantenidos a 30 ºC tienen una mediana de la concentración plasmática móvil de aproximadamente la mitad que los animales criados a 18 ºC y tratados con las mismas dosis. Por otra parte, las dosis crecientes determinaron un aumento de aproximadamente el doble de las medianas de la concentración plasmática. El modelo propuesto permitió cuantificar el impacto de la temperatura en los parámetros farmacocinéticos, además de estimar las concentraciones plasmáticas de florfenicol para tilapia a diferentes temperaturas de crianza.


  • Avaliação morfológica da glândula pineal de éguas em atividade reprodutiva e em anestro fisiológico

    by Henrique Ribeiro Alves de Resende, João Vitor Fernandes Cotrim de Almeida, João Bosco Costa Coelho, Lucas Wamser Fonseca Gonzaga, Marcos Ferrante, Edson Aparecido Liberti, Francisco Javier Hernandez Blazquez, Luciano da Silva Alonso, Wirton Peixoto Costa, Irvênia Luiza de Santis Prada

    A glândula pineal (GP), integrante do epitálamo, mostra-se sensível à luz e, nos vertebrados, secreta melatonina, na ausência de luminosidade. Este hormônio parece interferir na adaptação das funções reprodutivas às condições de luminosidade, especialmente, em animais que se reproduzem sazonalmente como os equinos, possibilitando o parto em épocas de clima mais quente e favorável à disponibilidade de alimentos. Diante disso, objetivou-se avaliar e descrever os componentes ultraestruturais da GP de 24 éguas, distribuídas em duas fases: estação de monta e anestro fisiológico, cada uma com 2 grupos (3-8 e 15-20 anos). A GP foi retirada após o abate dos animais e processada em etapas de fixação, secções histológicas e colorações. A análise do material processado foi realizada utilizando-se microscopia de luz e de transmissão. Os dados foram submetidos à análise estatística. A GP foi encontrada no plano sagital mediano, dorsocaudalmente à aderência intertalâmica e ventralmente ao esplênio do corpo caloso, apresentando formato ovoide ou piriforme. Estava envolvida por cápsula de tecido conjuntivo, da qual partem septos que, acompanhados por vasos sanguíneos, dividem o parênquima em lóbulos. Os principais componentes glandulares foram pinealócitos e astrócitos. Concreções calcárias foram evidenciadas no núcleo e no citoplasma de pinealócitos, bem como no espaço extracelular de todas as GPs, independentemente da idade e/ou fase reprodutiva. Por outro lado, animais em anestro fisiológico apresentaram maior número de pinealócitos.